Pharmacokinetics, Tissue Distribution and Identification of Putative Metabolites of JI-101 – A Novel Triple Kinase Inhibitor in Rats

Abstract

JI-101, chemically 1-[1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl]-3-(5-bromo-2-methoxy-phenyl)-urea hydrochloride, is a novel orally active kinase inhibitor, which has shown potent in vitro and in vivo anticancer activity against a variety of cancer cell lines and xenografts. It is currently entering Phase II clinical development for the treatment of solid tumors. The aim of the study is to assess the metabolic stability of JI-101 in various pre-clinical and human liver microsomes, to identify the major CYPs (cytochrome β450) involved in the metabolism of JI-101 and identification of putative metabolites. We have also studied the pharmacokinetics, tissue distribution and excretion of JI-101 in Sprague Dawley rats. JI-101 was found to be stable in various liver microsomes tested. JI-101 is highly permeable and not a substrate for P-gp (permeability glycoprotein). JI-101 excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 was rapidly absorbed, reaching C_max within 2 h. The t_½ of JI-101 with intravenous and oral route was found to be 1.75±0.79 and 2.66±0.13 h, respectively. The Cl and Vd by intravenous route for JI-101 were found to be 13.0±2.62 mL/min/kg and 2.11±1.42 L/kg, respectively. The tissue distribution of JI-101 was extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces.

Key words

JI-101 - kinase inhibitor - rats - pharmacokinetics - tissue distribution - metabolites - bile - excretion

• References

• 1 Velleca M, Brittelli D, Elkin L et al. Preclinical and preliminary phase 1 trial results of JI-101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFRβ. AACR-NCI-EORTC International Conference - Molecular Targets and Cancer Therapeutics 2009, November 15–19, Boston, MA, USA, Abstract no: B11
• 2 Sharma S, Miller L, Gordon M et al. Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2 and PDGFRß. Poster presentation at 22^nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics November 16–19, Berlin, 2010, Abstract no: 400
• 3 Rath L, Hutchison M. A new method for bile duct cannulation allowing bile collection and re-infusion in conscious rat. Lab Anim 1989; 23: 163-168
• 4 Gurav SD, Gilibili RR, Jennifer S et al. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101 in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: Application to a pharmacokinetic study. Biomed Chromatogra 2011; accepted DOI: 10.1002/bmc.1518).
• 5 Rao MN, Biju B, Ansar AK et al. Open access generic method for continuous determination of major human CYP 450 substrates/metabolites and its application in drug metabolism studies. Xenobiotica 2003; 33: 1233-1245
• 6 Karoor V, Le M, Merrick D et al. VEGFR-2 targeted chemoprevention of murine lung tumors. Cancer Prev Res (Phila Pa) 2010; 3: 1141-1147
• 7 Dev IK, Dornsife RE, Hopper TM et al. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. Br J Cancer 2004; 91: 1391-1398